Skip to content

Nursing Research on CRS Risk Warning for Patients with Hematological Malignancies Receiving CAR-T Therapy

Study on the construction of early risk warning and nursing countermeasures for CRS in patients with hematological malignancies undergoing nurse-led CAR-T therapy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600127843
Enrollment
Unknown
Registered
2026-07-08
Start date
2026-06-25
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological malignancies, CAR-T therapy-related cytokine release syndrome (CRS)

Interventions

Observation group:None

Sponsors

The Affiliated Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients with hematological malignancies who received CAR-T treatment; 2.Age >= 18 years.

Exclusion criteria

Exclusion criteria: 1.Patients with hematopoietic stem cell transplantation bridging CAR-T treatment; 2.Patients with incomplete vital signs after CAR-T infusion;

Design outcomes

Primary

MeasureTime frame
Occurrence of cytokine release syndrome ( CRS );Onset time of Cytokine Release Syndrome (CRS);Severity grading of Cytokine Release Syndrome (CRS);

Secondary

MeasureTime frame
Sensitivity of the early identification of CRS by the early warning system;Specificity of the early identification of CRS by the early warning system;Adverse events (such as fever, hypotension, and breathing difficulties);

Countries

China

Contacts

Public ContactHuang Baokui

The Affiliated Hospital of Xuzhou Medical University

953352931@qq.com+86 516 85806980

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026